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Summary The interference by BCG in the induction and expression of a specific antitumoral immune
reaction was studied in B6 mice, using the in vivo Winn assay and also active immunization. T cells
immunized against MCA-induced fibrosarcoma (MC B6-1) transferred together with the tumour cells
protected the syngeneic host against tumour take. Pretreatment of normal B6 mice with moderate or high
doses of BCG prevented the development of a protective immune response after immunization. Moreover, a
single dose of 1 mg, or 2 doses of 0.01 mg BCG, completely eliminated an established antitumour immunity.
Suppressor cells are involved in the BCG-induced inhibitory effect; they interfered (1) with the expression of
the antitumour response, since their addition to immune T cells in the Winn test resulted in decreased
protection and (2) with the induction of the antitumour response, since injection of spleen cells from BCG-
treated mice (BCG SpC) into normal mice before immunization inhibited the development of immunity.
Treatment of BCG SpC with anti Thy 1.2 and anti Lyt 1.2 antibodies plus complement before injection into
normal mice significantly decreased the suppressive activity, showing that the suppressor cells induced by
BCG are T cells expressing the Lyt 1+ phenotype. The partial increase in protection obtained after IL-2
administration to BCG-treated mice suggests that the suppressive action of BCG SpC on the IL-2 producing
capacity of helper T cells is only one of a number ofpossible mechanisms of T-cell-mediated suppression.
BCG treatment has been shown to induce tumour
regression by stimulating cell-mediated immunity
(Old et al., 1959; Zbar et al., 1970; Baldwin et al.,
1976). However, numerous studies have established
that treatment with high doses of BCG provoked
suppressive effects, revealed by inhibition of
reactions such as lymphocyte proliferation
(Turcotte et al., 1978), delayed-type hypersensitivity
(Watson & Collins, 1980; Florentin et al., 1976), T
cell cytotoxicity developed by mixed lymphocyte
culture (Klimpel & Henney, 1978; Davies &
Sabbadini, 1977), or antibody production (Schrier
et al., 1980; Kitamura et al., 1976). Recently,
Kendall & Sabbadini (1981) demonstrated that
BCG treatment could reduce the production of
helper factors (IL-2) capable of stimulating T cell
growth, and Klimpel et al. (1979) found that this
deficit in IL-2 synthesis by helper T cells could be
overcome by the in vitro addition of exogenous
IL-2.
We have used the test of adoptive transfer of
immunity (Winn, 1961) to study the effects of BCG
treatment on the induction of an in vivo T cell-
mediated specific immune response to tumour
antigen. This model has allowed us to study the
interactions of BCG at different phases (induction
and expression) of the T cell-mediated protective
mechanism against a chemically-induced tumour.
We have previously demonstrated that B6 mice can
be immunized against MC B6-1 tumour cells, a
MCA-induced fibrosarcoma, and that immune T
cells transferred together with MC B6-1 tumour
cells protected the syngeneic host against tumour
take. This control of tumour growth in vivo was the
result of a complex immunologic mechanism
involving cooperation between immunized T
lymphocytes and a radio-resistant non T cell of
host origin (Poupon et al., 1981).
In the present study we report that BCG at high
doses, injected before immunization, can completely
prevent the generation of specific protective T cells,
or even abrogate an already established antitumour
immunity. We demonstrate the presence of
suppressor cells in the BCG-treated animals, since
transfer of BCG spleen cells to normal mice
inhibited the development of active immunity. Also,
the addition of lymphoid cells from BCG-treated
mice to immune T cells before transfer to recipient
mice abrogated passive protection against tumour
growth. These suppressor cells belong to the T cell
subpopulation expressing the Lyt 1 phenotype. An
attempt to eliminate the suppressive effect of BCG
treatment by administration of a lymphocyte helper
factor (IL-2) had only a limited success.
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Materials and methods
Mice
Female 8- to 12-week-old C57BL/6 (B6) H-2b
haplotype mice were obtained from Bom Holtgaard
Laboratories (Denmark).
BCG
From Pasteur Institute, containing 7 x 106 viable
unitsmg-1, was administered i.v. to B6 mice at
different doses.
Tumour
The MC B6-1 fibrosarcoma was originally induced
by the s.c. injection of 2mg of methylcholanthrene
(MCA) into female B6 mice, and was then serially
transplanted in syngeneic females. MC B6-1 was
used between the 19th and 24th passages, at a
routine dose of 104 cells, which produced a
palpable tumour within 7-14 days in 96% of mice
(calculated on >200 mice). Tumour cells were
dissociated from the solid tumour by trypsinization
at 37°C for 90min. After washing, the number of
viable cells, determined by trypan blue exclusion,
always exceeded 90%.
Immunizations
Two protocols of tumour immunization were used,
one with living MC B6-1 tumour cells, the other
with AB2 hybrid tumour cells, which are semi-
allogeneic somatic hybrid cells derived from the
fusion of a MC B6-1 tumour cell and a A9 cell (a
fibroblastic cell of C3H origin).
(i) Immunization with MC B6-1 tumour cells The
immunization protocol has been described
previously (Poupon et al., 1979). B6 mice received
an initial s.c. injection of 5 x 105 cells obtained from
a solid tumour. After 10 days, the resulting tumour
was surgically removed. The mice then received
challenges of tumour cells at 21-day intervals, and
at progressively increasing doses; any tumour take
was followed by surgical removal. After the 5th
challenge, mice were able to reject a dose of 105
tumour cells and were thus considered immune.
(ii) Immunization with AB2 hybrid tumour
cells This immunization protocol, described
previously (Payelle et al., 1981), used a single
hybrid cell inoculation. These AB2 hybrid cells did
not produce tumours when injected into B6 mice
because of the presence of the H-2k histo-
compatibility antigens of the allogeneic A9 parental
cell. They did, however, induce antitumour
immunity against the syngeneic MC B6-1 parental
tumour cell. AB2 hybrid cells were maintained in
culture and injected as a single dose of 5 x 106 i.p.
Eight days after AB2 inoculation, mice were able to
reject a graft of 104 MC B6-1 tumour cells and
were, therefore, also considered immune.
Preparation of T cell suspensions
As previously described (Poupon et al., 1979),
spleens were removed from mice, dissociated,
filtered through a stainless steel sieve and washed in
MEM. To separate the T cell-enriched population,
108 total spleen cells in 2ml MEM plus 10% FCS
were placed on a column of 0.2g nylon wool (LP-1
leucopak leukocyte filter; Fenwall Laboratories,
Morton Grove, IL), incubated for 60min at 37°C,
and rinsed with 15ml MEM 10% FCS at 37°C
(Julius et al., 1973). The percentage of harvested
cells varied between 20 and 30%.
Procedurefor Winn assay
MC B6-1 tumour cells (104) were mixed with
immunized T cells in a volume of 0.2ml of MEM
at various T cell-tumour ratios as indicated in the
text. Each group consisted of 8 or 10 mice which
were checked every 2 or 3 days. The number of
tumour-bearing animals was recorded and the
growth rate was followed for 30 days.
Test ofresistance
AB2 hybrid tumour cell immunized mice,
previously treated by BCG or non-treated
(controls) received an injection of 104 MC B6-1
tumour cells s.c. in the flank. Groups of 10 mice
were identically treated. After one week, the mice
were checked every 2 to 3 days. The number of
tumour-bearing animals was recorded.
Transfer system
Spleen cells from normal (N-SpC) or BCG-treated
(BCG SpC) mice were injected i.v. into syngeneic
hosts as populations that were either unfractionated
(5 x 107 cells/mouse), anti Thy 1.2 treated (5 x 107
treated cells/mouse), or separated by passage
through a nylon-wool column (2 x 107 cells/mouse).
In some experiments the T cell enriched population
(2 x 107 nylon non-adherent cells/mouse) were
treated with Lyt 1.2 or Lyt 2.2 antisera+C before
administration. The mice receiving the various
populations of BCG SpC received 5 x 106 AB2
hybrid cells 2h later.
Treatment of spleen cells with monoclonal anti Thy
1.2 antibody and complement
Spleen cells (30 x 106) were placed for 1 h in an ice
bath with 0.5ml of a 10-3 dilution of monoclonal
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cells were then washed and resuspended in 1.5ml of
a 1:25 dilution of rabbit complement (Cedarlane
Laboratories Ltd, Canada) for 45min at 37°C in a
water bath with agitation.
Treatment of splenic T cells with monoclonal anti
Lyt 1.2 or anti Lyt 2.2 antibody and complement
Splenic T cells obtained after passage through a
nylon wool column (3 x 107) were placed for 1 h in
0.5ml monoclonal anti Lyt 1.2 or anti Lyt 2.2
antibody (New England Nuclear), at a 1:100 and
1:50 dilution respectively. The cells were then
washed and resuspended in 1.5ml ofa 1: 25 dilution of
rabbit complement (Cedarlane Laboratories) for
45min at 37°C in a water bath with agitation.
IL-2
IL-2 was a generous gift of Dr Chaouat, IRSC,
Villejuif, France. It was produced by stimulating
the EL4 C-16 cell line for 24h with phorbol-12-
myristate acetate. This preparation contained
400uml-1. IL-2 was adninistered i.p. daily to B6
mice at a dose of 20 u four days before, and 4 days
after, AB2 hybrid tumour cell immunization on
Day 0. In this experiment, mice received BCG i.v.
on Day 14 at a dose of 1 mg.
Enumeration ofBCG spleen colonies
Spleens were prepared in sterile distilled water and
serial dilutions were made from 1/50 to 1/40000.
One hundred ,ul of every suspension was inoculated
into tubes containing Jensen medium. The number
of colonies was enumerated 3 weeks later for each
dilution and the total number of colonies per spleen
was calculated.
Statistical evaluation
Statistical significance of differences between groups
was calculated using Fisher's exact test.
Results
Effect of BCG treatment on immunization against
tumour cells
Active immunization B6 mice received i.p. 2 x 106
AB2 hybrid tumour cells 14 days after BCG
administration at different doses. Eight days later, a
s.c. challenge of 104 MC B6-1 cells was given to
these mice. The effect of BCG on the level of
immunity produced by AB2 hybrid tumour cells
was evaluated by the number of mice developing
tumours in each group. Treatment with 1 mg BCG
led to a significantly decreased (P<0.01) efficiency
of the immunization, resulting in a loss of
resistance, even at the lowest doses (P=0.03)
(Table I).
Table I Effect of BCG pretreatment of immunized mice
on their resistance to tumour challenge
No. ofmice with tumourb
Dose ofBCGa T P valuesc
Total no. ofmice
(mg)
0 6/16
0.05 12/15 P=0.03
1 16/16 P<0.001
'BCG was injected i.v. on day -14, AB2 cells i.p. on
Day 0, and MC B6-1 tumour s.c. on Day 7.
bRecorded on Day 30.
cCompared with control group receiving no BCG
treatment.
Adoptive immunization B6 mice received 5 x 106
AB2 hybrid tumour cells i.p. 14 days after
administration of 0.05mg, 1 mg, or 5mg BCG per
mouse. Spleens were excised 7 days later and T cells
were enriched by passage through a nylon wool
column. Different numbers of T lymphocytes from
N-SpC or BCG-SpC were mixed with 104 tumour
cells (MC B6-1 fibrosarcoma) and injected s.c. into
syngeneic hosts. Table II shows that protection
against tumour take was obtained by transfer of T
lymphocytes originating from non BCG-treated
immunized mice, at both splenic T cell-to-tumour
cell ratios (300:1 and 150:1). When BCG was
administered before immunization, the number of
animals with tumours increased as the dose of BCG
increased. For the dose of 5mg, no protection at all
was observed (P<0.01). At the 300:1 and 150:1
Table II Effect of BCG pretreatment of
immunized mice on the protection of adoptively
transferred mice
No. ofmice with tumourb
Total no. ofmice
Dose ofBCG'
(mg) 300: c 150:1
0 8/18 8/20
0.05 4/10 4/10
1 12/18 18/20
5 18/20d 18/20d
aImmunization i.p. with AB2 cells was
performed 14 days after i.v. BCG or control
injection. Seven days later immune T spleen
cells were mixed with tumour cells and
transferred s.c. to normal recipient mice.
bRecorded on Day 30.
cImmune T spleen cell:tumour cell ratio.
dSignificantly different (P<0.01) from control
group receiving no BCG treatment.762 B. PAYELLE et al.
lymphocyte: tumour cell ratios the lowest dose
(0.05 mg BCG) allowed a good protection.
Influence of BCG on an established antitumour
immunity
In this experiment B6 mice were immunized by
progressively increasing the challenge dose of live
MC B6-1 cells and excising any subsequent
tumours. After 5 tumour cell challenges (protocol
under Table III), all mice were able to reject a
tumour graft of 1 x 105 cells. At that time,
immunized mice received 0.01 mg or 1 mg BCG i.v.
and a 105 MC B6-1 tumour cell challenge was
performed 12 days later. After an additional 10
days, immune splenic T cells from the different
groups of animals were transferred to normal
recipient mice together with MC B6-1 cells in a
Winn assay. Results giving the percentage of
tumour-bearing recipient mice are presented in
Table III. Passive protection against tumour growth
was improved by 0.01 mg BCG administration
(78% versus 50% in control mice at 600:1 lympho-
cyte to tumour cell ratio) given before the last
tumour cell challenge. In contrast, an injection of
mg BCG abrogated the passive transfer of
immunity (100% tumour take) (P=0.05).
Table III Effect of BCG on pre-existing anti-
tumour immunity
No. ofmice with tumourb
Total no. ofmice
Dose ofBCG'
(mg) 600: c 300:1
0 5/10 8/8
0.01 2/9 5/8
1 8/8 7/8
aImmune mice received 10 days after the 5th
challenge of 105 live tumour cells s.c., either
0.1 ml PBS i.v., or 0.01mg BCG i.v., or 1 mg
BCG i.v. Twelve days later all the mice received
a 6th challenge of 105 live MC B6-1 tumour
cells s.c. Winn test was performed 10 days later.
bRecorded Day 30.
cImmune T spleen cell:tumour cell ratio.
dp =0.05 compared with control group
receiving no BCG treatment.
In a second experiment, groups of mice were
prepared as described in the protocol under Table
IV. All immunized mice having received a second
injection of 1 mg BCG developed tumours,
therefore were not rechallenged with MC B6-1
tumour cells, and died rapidly. No tumours were
observed either in the control immune group
receiving PBS and MC B6-1 cells, or in the group
receiving 0.01 mg BCG +MC B6-1 cells. In order to
determine whether the efficiency of immunization
mediated by T cells could be further increased, a
second BCG injection of 0.01 mg was given to these
mice followed by MC B6-1 inoculation 12 days
later (protocol under Table IV). Splenic T cells
were then transferred to syngeneic hosts mixed with
tumour cells. We observed that 87% of the mice
were still protected against tumour growth in the
control group, but that the second injection of
O.Olmg BCG significantly (P<0.05) abrogated the
protective effect of previous immunization (Table
IV). From both of these results, it may be
concluded that high doses of BCG not only
reduced the efficiency of immunization, but also
abrogated an established immunity, Moreover,
while a small dose was able to increase the
efficiency of immune T cells, its repetition led to the
same effect as one high dose.
Table IV Effect of repetition of BCG on a
pre-existing immunity
No. ofmice with tumourb
Total no. ofmice
Dose ofBCG'
(mg) 600: c 300:1
0 1/8 1/8
0.01 6/8e 8/8e
id
aImmune mice received, 10 days after a 5th
challenge of 105 live tumour cells s.c., either
0.1 ml PBS i.v., 0.01mg BCG i.v., or 1mg BCG
i.v. Twelve days later all the mice received a 6th
challenge of 105 live tumour cells s.c. Each
group then received respectively 0.01 ml PBS,
0.01mg BCG, or 1mg BCG 10 days after the
6th tumour cell challenge. A 7th tumour cell
challenge was performed 12 days later followed
by Winn test 10 days later.
bRecorded on Day 30.
clmmune T spleen cell:tumour cell ratio.
dThese mice were not tested since they had
growing tumours and died rapidly after the
second injection of BCG.
eSignificantly different (P<0.05) from control
group receiving no BCG treatment.
Since the BCG used is a live vaccine, the number
of colonies in the spleen of mice injected with
0.05mg became similar to that observed with 1 mg
at Day 14, although with a delay of 21-28 days
(Figure 1). Therefore, the application of a small
dose such as 0.01 mg BCG twice at a 3 week
interval may give rise to a similar bacterial load to
that obtained with an inoculum of 1 mg BCG 14
days before. This may lead to the deterioration of
the protective effect of cytotoxic T cells against
tumour growth.BCG AND SPECIFIC ANTITUMORAL IMMUNE RESPONSE 763
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Figure 1 Number of BCG colonies in the spleen of
mice treated i.v. with 0.05mg ( ), 0.2mg (--),
or 1 mg (----) BCG as a function of time after i.v.
administration.
Evidencefor suppressor cells in BCG-treated mice
In order to demonstrate a suppressive activity
mediated by cells present among BCG-SpC, a cell
mixture experiment was performed as follows: 107
spleen cells from 0.05mg or 1 mg BCG-treated mice
were added to 4 x 106 immune T cells and 104
tumour cells. This mixture was transferred to
syngeneic hosts. The control group consisted of
mice receiving N-SpC with immune T cells and
tumour cells (Table V). We observed some degree
of protection in the control group (6/18 mice
developed tumours). The addition of 107 0.05mg
BCG SpC did not modify the antitumour
protection (Table V). In contrast, the addition of
107 1 mg BCG-SpC resulted in a significant
(P<0.02) decreased protection (14/18 mice with
tumours). These observations demonstrated that
high dose BCG induced suppressor cells that act
during the effector stage of the antitumour immune
reaction.
A second approach was to determine the effect of
these cells on the development of antitumour
immunity. We injected i.v. N-SpC or 1 mg BCG-
SpC into syngeneic B6 hosts which received AB2
hybrid cells 2 h later. Eight days later, splenic T
cells from these i.v. injected immunized mice were
tested for their protective activity in a Winn assay.
Figure 2 illustrates the results obtained after i.v.
injection of 1 mg BCG-SpC; either the whole
population, or the T-enriched (nylon-wool non-
adherent) or T-depleted (anti 0 treated) population.
In these particular experiments, the inhibition of
the protective effect by previous injections of BCG-
SpC was moderate. However, when BCG-SpC were
injected after purification we observed an amplified
inhibition by the T-enriched population and a loss
of inhibition of protection by the T-depleted
population (Figure 2).
In order to determine the phenotype of the T
cells responsible for this suppression, T-enriched
1 mg BCG-SpC were treated with anti Lyt 1.2 or
anti Lyt 2.2 antibodies +C. The transfer of the
whole population as well as the T-enriched BCG-
SpC actively suppressed the immunization of
normal hosts (Figure 3). This suppression was
found to be mediated by the Lyt 1 subpopulation
of T cells since anti Lyt 1 treatment abrogated this
suppressive effect, whereas anti Lyt 2 treatment had
no effect (Figure 3).
Effect of in vivo IL-2 administration on the
suppressive activity induced by BCG pretreatment
It has previously been assumed that a deficiency in
the activity of helper factors might be a major
cause of the reduced in vitro cytotoxicity developed
by lymphocytes of BCG-treated mice (Kendall &
Sabbadini, 1981). We attempted to test such a
hypothesis as an explanation of the inhibitory
effects on the antitumoral immune response
observed after BCG treatment. In order to
Table V Effect of addition, in the Winn test, of spleen cells from normal or BCG-treated mice
on the protection transferred by immune T lymphocytes
No. ofmice with tumour/total no. ofmicea
Spleen cellsbfrom mice treated with thefollowing doses ofBCG
Normal spleen cellsb 0.05mg Img
6/18 3/8 14/18C
aRecorded on Day 30.
blO7 spleen cells from normal or BCG-treated mice were added to 4 x 106 immune T cells and
I04 tumour cells (E:T=400: 1).
CSignificantly different (P<0.02) from control group receiving no BCG treatment.
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Figure 2 Evidence of suppressor cells induced by
1 mg BCG. B6 syngeneic mice received i.v. 2h before
AB2 immunization NSpC (U), BCG SpC either the
whole population (A) or T cell-depleted (A) or T cell-
enriched (0) BCG SpC populations. Eight days later
5 x 106 immune T spleen cells derived from mice of the
different groups were mixed with 104 B6-1 tumour
cells and injected s.c. to syngeneic B6 mice. Tumour
growth of the mixtures was measured and compared
to the growth of 104 B6-1 tumour cells alone (----@).
overcome this deficiency, we repeatedly
administered in vivo exogenous IL-2, after BCG
treatment. BCG, IL-2 and AB2 hybrid cells were
given according to the protocol described in
Materials and Methods. Protection against tumour
growth obtained after immunization with AB2
hybrid cells was nearly abolished by pretreatment
with 1 mg BCG and also, surprisingly after IL-2
repeated administration (Figure 4). The
combination of BCG and IL-2 treatments decreased
the inhibitory effect of BCG treatment.
Discussion
The question addressed was whether BCG
interferes with a specific in vivo antitumoral
immune reaction and whether this interaction
depends upon the dose of BCG and the state of
immunization. The expression of active immunity
conferred by an AB2 hybrid tumour cell
inoculation was eliminated by a previous BCG
injection, even at low doses. The mechanism
responsible for tumour rejection in this model
might be either nonspecific (NK, macrophages) or
specific (immune T cells). The method of
transferred immunity (Winn assay) circumvented
the problem of nonspecific resistance which exists
in actively immunized recipients and permitted the
study of the effects of BCG on specific immunity
mediated by T cells.
We have previously shown (Poupon et al., 1979,
1981) that a specific response could be developed
against tumour cells dissociated from MCA fibro-
sarcoma in B6 mice. Two types of immunizing
protocols were used: the first consisted of
repeatedly challenging B6 syngeneic mice with live
tumour cells, followed by surgical excision of the
tumour (Poupon et al., 1979). The other consisted
of a single injection of tumour cells hybridized with
an allogeneic cell (Payelle et al., 1981). These two
different types of immunization resulted in an
identical immune reaction characterized by a sharp
specificity against the tumour cells and the
transference of this immune protection only by T
cells. Both types of immunization have been used in
this study, depending on the question addressed.
Interactions between BCG treatment and the anti
MC B6-1 antitumoral reaction were studied at
different phases of the development of the immune
state. The pretreatment of normal mice by low
doses of BCG did not modify the level of the
protective effect induced by injection of hybrid
tumour cells. In some experiments, such BCG
treatment even tended to result in a better response
to the tumour antigen. A high dose of BCG (1 mg),
however, dramatically inhibited the emergence of
an immune response. Such a negative effect has
previously been shown by many authors (Davies &
Sabbadini, 1977; Florentin et al., 1976; Turcotte et
al., 1978; Geffard & Orbach-Arbouys, 1976;
Watson & Collins, 1980; Klimpel, 1979), and our
results confirm this finding.
A further important question concerned the
interference of BCG treatment with an established
antitumoral immune state. We demonstrated that
BCG effects were complex. At low doses (0.01 mg),
BCG had a potentiating effect on the immune
response. In contrast, a high dose of BCG (1 mg)
completely abolished the pre-existing immunity.
This was shown both by the loss of the protective
effect of T lymphocytes originating from previously
immunized mice, and by the death of the
immunized mice following rapid tumour growth; a
phenomenon which is not normally observed at this
stage of immunization. When the small dose was
repeated, the benefit was lost. This might be linkedBCG AND SPECIFIC ANTITUMORAL IMMUNE RESPONSE 765
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Figure 3 Characterization of suppressor cells induced by 1 mg BCG. B6 syngeneic mice received 2h before
AB2 immunization N SpC (U), BCG SpC either the whole population (A), or T cell-enriched (0) or T cell-
enriched anti Lyt 1-treated (Ol) or T cell-enriched anti Lyt 2-treated (A) BCG SpC populations. Eight days
later 5 x 106 immune T spleen cells derived from mice of the different groups were mixed with 104 B6-1
tumour cells and injected s.c. to syngeneic B6 mice. Tumour growth of the mixtures was measured and
compared to the growth of 104 B6-1 tumour cells alone (O---@).
to the progressive development of BCG colonies in
the spleen of the treated mice.
In our experiment, two administrations of low
doses of BCG at a 22-day interval followed by
tumour challenge 10 days later, resulted in an
elevated number of bacilli that was more rapidly
obtained in the case of a high dose of BCG.
Therefore, it is not surprising that similar inhibitory
effects were observed in both situations if these
effects are linked to the development of BCG
colonies. Several possibilities to explain inhibitory
effects have to be considered: (i) production of
BCG-induced-blocking factors which enhance
tumour growth. These factors have been demon-
strated in different tumour systems both in mice
(Hawrylko, 1977) and rats (Bansal et al., 1973). (ii)
The induction of suppressor cells which are active
at the effector phase of the specific antitumoral
protection. Our results suggested the presence, in
the spleen of mice treated with high dose BCG, of
suppressor cells active on the effector phase of the
specific antitumoural response. We demonstrated
more directly the presence of suppressor cells which
develop after BCG treatment by a direct effect on
immune activity through mixing BCG suppressor
cells with immune lymphocytes. These experiments
clearly showed the inhibitory effect of BCG-SpC on
the protective effect of transferred immune T cells.
A second phase of these studies demonstrated that
suppression also acts at the induction stage of
immunization. We showed a suppression of the
generation ofimmune T cells mediated by nylon-non
adherent cells derived from 1 mg BCG treated mice.
This suppression was eliminated by the treatment of
BCG-SpC with anti Thy 1.2 +C before the
transfer. Treatment with anti Lyt 1.2 + C
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Figure 4 Effect of IL-2 supplementation on the suppressive activity of BCG pretreatment. Growth of
tumours in mice receiving tumour cells alone (S), or mixed with immune T cells (U), or with T cells derived
from BCG (1 mg) treated immune mice (A), or with T cells derived from IL-2 supplemented immune mice
(El) or with T cells derived from BCG (1 mg) pretreated IL-2 supplemented immune mice (A).
eliminated the suppressor activity of the BCG-T cell
population whereas treatment with anti Lyt 2.2 +
C did not affect the suppression. Therefore, the
suppression induced by high dose BCG is mediated
by Lyt 1 2 - T cells. It was recently demonstrated
that antigen nonspecific suppression of cytotoxic T
lymphocyte responses to alloantigen is also
mediated by a T cell of Ly 1+2- phenotype
(Hathcock & Hodes, 1983). The presence of
suppressor macrophages was shown to be
operative, using mainly in vitro systems (Shrier et
al., 1980; Klimpel et al., 1979; Wadee et al., 1980).
Suppressor T cells have been implicated in the
inhibition of DTH reactions (Nakamura et al.,
1982; Kato & Yamamoto, 1982; Watson & Collins,
1980), lymphoproliferative responses (Florentin et
al., 1976) and GVH reactivity (Geffard & Orbach-
Arbouys, 1976).
Several mechanisms of T cell mediated
suppression have bee postulated by the different
workers: (i) an increased absorption of helper
factors by the suppressor cells (Klimpel et al.,
1979); (ii) an alteration of the kinetics of the
interaction between the cytotoxic cells and their
targets during the T cell mediated cytotoxicity
(Davies & Sabbadini, 1978); (iii) an inhibition of
the capacity of Lyt 1+ T cells to produce helper
factors (Klimpel et al., 1979; Kendall & Sabbadini,
1981), since in vitro addition of exogenous IL-2
completely restored the response. Kendall &
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Sabbadini (1981) suggested two hypotheses for the
reduced capacity of Lyt 1 T cells to produce IL-2;
the direct action of BCG on these Lyt 1' cells, or
the mediation of BCG-induced suppressor cells.
Combined BCG and IL-2 treatment was followed
by delayed tumour growth as compared to BCG
given alone. But, since IL-2 given repeatedly to
immunized mice abrogated the protection, the
interaction between the effects of IL-2 and BCG
appears very complex and interpretation of these
results is difficult. Our results clearly demonstrate
that T suppressor cells of the Ly 1 2- phenotype
are responsible, at least partially, for the reduced
response induced by high dose BCG. Other
mechanisms, beside the intervention of a
suppressive activity, have been demonstrated to be
implicated in the reduced response of BCG-treated
animals: a reduced frequency of CTL precursors
(Kendall & Sabbadini, 1981), an acceleration of the
destruction of antigen (Perkins & Makinodan,
1965), a blockade of the RES (Sabet et al., 1969).
This work confirms the complex effects of BCG,
which may be beneficial or harmful to the immuno-
logical control of tumour growth, depending upon
its mode of application, and especially on the
dosage used. We demonstrated that BCG induces T
suppressor cells, active on the afferent and on the
efferent arm of the anti-tumour immune response.
BCG also stimulates macrophages with antitumour
activity. These contradictory activities are
important to consider when using BCG in cancer
therapy.
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IL-2. We thank V. Chanoina and I. Vergnon for their
excellent technical assistance.
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